Pfizer Amps up Push Into Obesity Treatments With $4.9B Deal for Metsera Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing ...
Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition. The COVID-19 vaccine and ...
Pfizer is doubling down on obesity treatments by spending $4.9 billion on the development-stage drugmaker Metsera. The COVID-19 vaccine and treatment maker said early Monday that it will pay $47.50 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback